BIIB

Biogen
D

BIIB

Arincen57/100B

Biogen EPS (earnings per share) 1985–2026

Biogen's diluted EPS in Q3 FY2026, the three months to 30 September 2026, was -0.14 USD, down 104.4% on the same quarter a year before. Biogen's diluted earnings per share over the last twelve months were 2.34 USD, down 78.7% on the twelve months before. In fiscal year 2025 they were 8.83 USD, down 21.1% on the year before.

Last updated 9 Nov 2026 · Next report 5 Feb 2027

EPS

Growth

Fiscal yearPeriod endingEPSGrowthEPS (basic)
TTM30 Sept 20262.34-78.71%2.36
FY202531 Dec 20258.83-21.09%8.85
FY202431 Dec 202411.19+40.40%11.20
FY202331 Dec 20237.97-61.81%8.02
FY202231 Dec 202220.87+100.67%20.97
FY202131 Dec 202110.40-58.06%10.44
FY202031 Dec 202024.80-21.07%24.86
FY201931 Dec 201931.42+45.60%31.47
FY201831 Dec 201821.58+81.04%21.62
FY201731 Dec 201711.92-29.59%11.94
FY201631 Dec 201616.93+10.37%16.96
FY201531 Dec 201515.34+24.01%15.38
FY201431 Dec 201412.37+58.39%12.42
FY201331 Dec 20137.81+35.59%7.86
FY201231 Dec 20125.76+14.29%5.80
FY201131 Dec 20115.04+27.92%5.09
FY201031 Dec 20103.94+17.61%3.98
FY200931 Dec 20093.35+26.42%3.37
FY200831 Dec 20082.65+33.17%2.67
FY200731 Dec 20071.99+215.87%2.02
FY200631 Dec 20060.63+34.04%0.64
FY200531 Dec 20050.47+571.43%0.48
FY200431 Dec 20040.07—0.07
FY200331 Dec 2003-2.62-624.00%-2.62
FY200231 Dec 20020.50-26.47%0.51
FY200131 Dec 20010.68-5.56%0.70
FY200031 Dec 20000.72+53.19%0.75
FY199931 Dec 19990.47+213.33%0.49
FY199831 Dec 19980.15+55.93%0.16
FY199731 Dec 19970.10+119.13%0.10
FY199631 Dec 19960.04+448.75%0.05
FY199531 Dec 19950.01—0.03
FY199431 Dec 1994-0.01-115.00%-0.01
FY199331 Dec 19930.04-11.11%0.04
FY199231 Dec 19920.05+571.64%0.05
FY199131 Dec 19910.01+103.03%0.01
FY199031 Dec 19900.00-59.76%0.00
FY198931 Dec 19890.01—0.01
FY198831 Dec 1988-0.01—-0.00
FY198731 Dec 1987-0.04—-0.04
FY198631 Dec 1986-0.06—-0.06
FY198531 Dec 1985-0.04—-0.04

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Biogen's EPS

Source: Financial Modeling Prep